Drugs / DA-020
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT07397325 Comparator | Apr → Oct 2026 expected | chemotherapy-induced alopecia, chemotherapy-induced toxicity | Applied Biology, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DA-020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07397325 ↗ |
| Known as | Oxymetazoline | “7mL application of DA-020 (Topical Oxymetazoline)” NCT07397325 ↗ |